LP-184 by Starlight Therapeutics for Melanoma: Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Melanoma.

#ASCO24: Novartis’ new CML treatment tops older drugs, including Gleevec, in Phase 3 trial

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 1, 2024

Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up

November 1, 2023

Opinion | Small Wins

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

March 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.